Jessica Caciolla

Jessica Caciolla

Auto-generated profile, based on publicly available information

Jessica Caciolla

Department of Pharmacy and Biotechnology, Alma Mater Studiorum─University of Bologna, Via Belmeloro 6, Bologna 40126, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ASAlessandra Salerno
Alessandra Salerno
FSFrancesca Seghetti
Francesca Seghetti
JCJessica Caciolla
Jessica Caciolla
EUElisa Uliassi
Elisa Uliassi
ETEleonora Testi
Eleonora Testi
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this technology, a growing paradigm toward enriching PROTACs with other therapeutic modalities has been proposed. Could researchers successfully combine two modalities to yield multifunctional PROTACs with an expanded profile? In this Perspective, we try to answer this question. We discuss how this possibility encompasses different approaches, leading to multitarget PROTACs, light-controllable PROTACs, PROTAC conjugates, and macrocycle- and oligonucleotide-based PROTACs. This possibility promises to further enhance PROTAC efficacy and selectivity, minimize side effects, and hit undruggable targets. While PROTACs have reached the clinical investigation stage, additional steps must be taken toward the translational development of multifunctional PROTACs. A deeper and detailed understanding of the most critical challenges is required to fully exploit these opportunities and decisively enrich the PROTAC toolbox.

1 November 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJessica Caciolla
Jessica Caciolla
Silvia MartiniSilvia Martini
Silvia Martini
Angelo SpinelloAngelo Spinello
Angelo Spinello
MPMatic Pavlin
Matic Pavlin
Eleonora TurriniEleonora Turrini
Eleonora Turrini
AMAlessandra Magistrato
Alessandra Magistrato

2 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CECécile Exertier
Cécile Exertier
ASAlessandra Salerno
Alessandra Salerno
LALorenzo Antonelli
Lorenzo Antonelli
AFAnnarita Fiorillo
Annarita Fiorillo
RORiccardo Ocello
Riccardo Ocello
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Trypanothione reductase (TR) is a suitable target for drug discovery approaches against leishmaniasis, although the identification of potent inhibitors is still challenging. Herein, we harnessed a fragment-based drug discovery (FBDD) strategy to develop new TR inhibitors. Previous crystallographic screening identified fragments 1-3, which provided ideal starting points for a medicinal chemistry campaign. In silico investigations revealed critical hotspots in the TR binding site, guiding our structure- and ligand-based structure-actvity relationship (SAR) exploration that yielded fragment-derived compounds 4-14. A trend of improvement in Leishmania infantum TR inhibition was detected along the optimization and confirmed by the crystal structures of 9, 10, and 14 in complex with Trypanosoma brucei TR. Compound 10 showed the best TR inhibitory profile (Ki = 0.2 μM), whereas 9 was the best one in terms of in vitro and ex vivo activity. Although further fine-tuning is needed to improve selectivity, we demonstrated the potentiality of FBDD on a classic but difficult target for leishmaniasis.